CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, leads discussion on longevity science and potential $600 billion addressable global market opportunity1 at the 12th Annual Dermatology Summit

Highlights Rubedo expansion plans at the J.P. Morgan Healthcare Conference 2025 side event “Italy on the Move”

SAN FRANCISCO: Rubedo Life Sciences, an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, announced its clinical development plans for its lead candidate RLS-1496 at the 12th Annual Dermatology Summit. RLS-1496 is a first-in-class GPX4 modulator that targets aging cells and surrounding tissues. Rubedo’s CEO Frederick Beddingfield, III, MD, PhD, FAAD, FACMS, led a discussion on longevity science and its potential $600 billion addressable global market opportunity while moderating a panel that included other longevity science experts and investors. Rubedo’s Chief Scientific Officer Marco Quarta, PhD, also presented details regarding the Phase 1 clinical trial for RLS-1496, which will begin in Spring 2025 in the Netherlands, and the kickoff of the company’s Series B financing round.

The Dermatology Summit, which Dr Beddingfield co-founded 12 years ago as part of the non-profit Advancing Innovation in Dermatology, was held alongside the J.P. Morgan Healthcare Conference 2025. Dr. Beddingfield also participated as a panelist at Biotech Showcase, discussing “Enhancing Longevity,” and at a J.P. Morgan side event “Italy on the Move,” hosted by the Italian Trade Agency and the Ministry of Foreign Affairs and International Corporation. Rubedo is headquartered in Silicon Valley with offices in Milan, Italy.

“Today, more than 1 billion adults are over the age of 60 and this number is expected to increase to 2 billion by 20502,” said Dr. Beddingfield. “Innovations to address the biological processes causing age-related chronic conditions, including heart disease, dementia, cancer, obesity, and metabolic syndrome, are needed to enable people to not only fight disease but also to empower a vibrant healthspan. At Rubedo, we are excited to be bringing the first selective cellular rejuvenation medicine that targets GPX4 into the clinic early this year. Our vision is to help adults live longer and healthier lives and we are delighted to be at the forefront of this new era in longevity science.”

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders. Our lead drug candidate – RLS-1496, a potential first-in-class disease-altering GPX4 modulator – enters Phase I clinical trials in Spring 2025. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Sunnyvale, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

1Newman P. Longevity Technology®. Bank of America analysts predict Longevity to be the opportunity of the decade. Published July, 2019. Accessed 13 January, 2025. Available: https://longevity.technology/news/bank-of-america-analysts-predict-longevity-to-be-the-opportunity-of-the-decade/

2 World Health Organization. Key Facts. Published October 20, 2023. Accessed 13 January 2025. Available: https://www.who.int/news-room/fact-sheets/detail/mental-health-of-older-adults#:~:text=Overview,conditions%20at%20the%20same%20time October 20, 2023.

Fonte: Business Wire